telaglenastat

• 

Telaglenastat plus cabozantinib in patients with metastatic kidney cancer

By Sharon Deveson Kell|2022-09-23T07:17:06+00:0023 Sep 2022|Drug treatments|

Cell metabolism in kidney cancer tumours is disrupted, and tumour [...]

Read More

Comments Off on Telaglenastat plus cabozantinib in patients with metastatic kidney cancer

• 

Telaglenastat plus everolimus in advanced kidney cancer

By Sharon Deveson Kell|2022-05-18T07:59:04+00:0018 May 2022|Drug treatments|

This phase 2 clinical trial (ENTRATA) looked at how safe [...]

Read More

Comments Off on Telaglenastat plus everolimus in advanced kidney cancer

• 

Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer

By Sharon Deveson Kell|2022-03-15T07:48:59+00:0015 Mar 2022|Drug treatments|

This phase 1 clinical trial looked at the safety, tolerability, [...]

Read More

Comments Off on Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer

• 

ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer

By Robert|2021-07-07T12:47:34+00:008 Jun 2021|Drug treatments|

Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, [...]

Read More

Comments Off on ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer

• 

CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival

By Sharon Kell|2021-01-06T15:21:37+00:006 Jan 2021|Drug treatments|

The US Food and Drug Administration (FDA) has granted the [...]

Read More

Comments Off on CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival

• 

ENTRATA study of telaglenastat in combination with everolimus in patients with kidney cancer

By Sharon Kell|2020-10-29T09:28:50+00:0029 Oct 2020|Uncategorized|

In this video interview Dr Chung-Han Lee from Memorial Sloan [...]

Read More

Comments Off on ENTRATA study of telaglenastat in combination with everolimus in patients with kidney cancer

• 

ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer

By Sharon Kell|2019-09-30T08:35:52+00:0030 Sep 2019|Drug treatments|

Results from the ENTRATA clinical trial to assess telaglenastat in [...]

Read More

Comments Off on ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer

• 

Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer

By Sharon Kell|2019-06-27T08:34:45+00:0027 Jun 2019|Drug treatments|

Telaglenastat is an oral glutaminase inhibitor and this is the [...]

Read More

Comments Off on Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer